Contineum Therapeutics, Inc. CTNM
9.79 USD +0.10 (+1.03%)
At closeNov 5, 2026, 4:48 AM EST
9.60 -0.19 -1.94%
Pre-market · Nov 5, 4:48 AM ET
9.56 Day range 10.32
6.73 52-week range 17.79
- YTD
- -14.35%
- 1 year
- -6.23%
Analyst view
Price target (mean) 29.25 +198.8% upside
Now 9.79
- Target (low)
- 25.00
- Target (mean)
- 29.25
- Target (high)
- 32.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.435 | -0.50 – -0.37 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Current year | -1.90 | -2.11 – -1.51 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next year | -1.62 | -2.03 – -0.71 | -1.90 | +14.9% | 10.00M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 22, 2024 | Baird | Initiated | — | Outperform |
| Aug 14, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 30, 2024 | RBC Capital | Initiated | — | Outperform |
| Apr 30, 2024 | Stifel | Initiated | — | Buy |
| Apr 30, 2024 | Morgan Stanley | Initiated | — | Overweight |